Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.
CALGB 40601（Alliance）HER2+乳腺癌新辅助治疗试验的蛋白质基因组学分析揭示了耐药生物标志物
期刊:Cell Reports Medicine
影响因子:10.6
doi:10.1016/j.xcrm.2025.102154
Jaehnig Eric J, Fernandez-Martinez Aranzazu, Vashist Tanmayi D, Holt Matthew V, Williams LaTerrica, Lei Jonathan T, Moon Chang In, Kim Beom-Jun, Dou Yongchao, Zhao Haoquan, Korchina Viktoriya, Gibbs Richard A, Muzny Donna Marie, Doddapaneni Harshavardhan, Perou Charles M, Carey Lisa A, Robles Ana I, Hyslop Terry, Wen Yujia, McCart Linda, Krek Azra, Petralia Francesca, Miles George, Kavuri Shyam M, Gillette Michael A, Mani D R, Carr Steven A, Zhang Bing, Ellis Matthew J, Satpathy Shankha, Anurag Meenakshi
